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Background: Although numerous candidate gene and genome-wide association studies have been performed on
blood pressure, a small number of regulating genetic variants having a limited effect have been identified. This
phenomenon can partially be explained by possible gene-gene/epistasis interactions that were little investigated so far.
Methods: We performed a pre-planned two-phase investigation: in phase 1, one hundred single nucleotide
polymorphisms (SNPs) in 65 candidate genes were genotyped in 1,912 French unrelated adults in order to study their
two-locus combined effects on blood pressure (BP) levels. In phase 2, the significant epistatic interactions observed in
phase 1 were tested in an independent population gathering 1,755 unrelated European adults.
Results: Among the 9 genetic variants significantly associated with systolic and diastolic BP in phase 1, some may act
through altering the corresponding protein levels: SNPs rs5742910 (Padjusted≤0.03) and rs6046 (Padjusted =0.044) in F7
and rs1800469 (Padjusted ≤0.036) in TGFB1; whereas some may be functional through altering the corresponding protein
structure: rs1800590 (Padjusted =0.028, SE=0.088) in LPL and rs2228570 (Padjusted ≤9.48×10
-4) in VDR. The two epistatic
interactions found for systolic and diastolic BP in the discovery phase: VCAM1 (rs1041163) * APOB (rs1367117), and
SCGB1A1 (rs3741240) * LPL (rs1800590), were tested in the replication population and we observed significant
interactions on DBP. In silico analyses yielded putative functional properties of the SNPs involved in these epistatic
interactions trough the alteration of corresponding protein structures.
Conclusions: These findings support the hypothesis that different pathways and then different genes may act
synergistically in order to modify BP. This could highlight novel pathophysiologic mechanisms underlying hypertension.
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Blood pressure (BP) is a continuous, consistent and modi-
fiable risk factor for cardiovascular diseases (CVD) such
as ischemic heart disease (IHD) and stroke which are
major causes of mortality and morbidity worldwide [1]:
population-based studies showed that 972 million adults
were hypertensive in 2005 and it is predicted to increase
by about 60% to 1.56 billion in 2025 [2].
Existing evidence suggests that BP heritability ranges
between 30-60% [3]. Despite the identification of specific
causal genes involved in the regulatory pathways of rare
familial forms of hypertension (HT) [4], both BP and* Correspondence: Sophie.visvikis-siest@inserm.fr
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reproduction in any medium, provided the orHT are still considered polygenic traits involving a large
number of metabolic pathways [5].
The complex architecture of BP regulation may ac-
count for the numerous discrepancies found among
studies of the genetic background of HT. Inflammation,
blood coagulation cascade, cellular adhesion molecules
and lipid metabolism all appear to have significant roles
[6-8]. While aspects of BP regulation may be the product
of an inflammation stimulus [6,9], thrombin is also
known to induce several intracellular pathways [7], to
modulate vascular tone [7,10] and to have pro-inflammatory
effects [7]. Growing evidence also suggests that cellular ad-
hesion molecules and apolipoproteins are closely related to
HT [8,11]. All of these factors may be involved in initiating
and maintaining elevated BP levels [7]. Overall, however, the
genetic factors associated with BP are poorly characterizedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ous studies remain unclear.
The advent of high-throughput genotyping assays raised
big expectations for a better identification of susceptibility
BP loci [12-15] but limited progress has been made so far:
the largest genome-wide association study (GWAS)
published until now included ≈200,000 individuals and
reported 28 loci associated with systolic BP (SBP), dia-
stolic BP (DBP) and/or HT [12]. However, their risk score
explained only 0.9% of BP phenotypic variance [12]. The
persistence of this so-called ‘dark matter’ of BP genetic
risk could be explained by the significant genetic and
phenotypic heterogeneity of populations studied as well as
the modest effect size of risk alleles [16]. In addition, con-
ventional GWAS are based on independent gene/single
nucleotide polymorphism (SNP) effects on a single pheno-
type without taking into account the possibility of two dif-
ferent genes/SNPs interactions that may affect the same
trait. Studying regulatory mechanisms exerted by a given
genetic variant modulating the effect of another i.e. epi-
static interactions may be essential [17] in identifying the
genes involved in BP regulation. Based on the above ra-
tionale [14,15,17], we hypothesize that research of epistatic
interactions among candidate SNPs may represent a chal-
lenge in the search for disease-risk variants as the effect of
one SNP may be altered or masked by the effects of an-
other SNP. Furthermore, power to detect the first SNP is
likely to be reduced and elucidation of the joint effects of
two loci will be hindered by their interaction, unless expli-
citly examined. In fact, it is well-known that these
interactions may identify genetic markers that are not
captured by individual marker analysis and/or revealed by
the combinatory effect of loci in other pathways [13,18].
As BP is a polygenic trait, where different metabolic
pathways are involved (inflammation, coagulation cas-
cade, sodium reabsorption, cellular adhesion and lipid
metabolism), we regrouped 100 previously published
cardiovascular candidate SNPs in 65 genes to perform a
well-powered two-phases statistical analysis in two large
independent populations in order to assess eventual epi-
static interactions having an effect on BP.
Methods
Ethics statement
The samples are part of a human sample storage platform:
the Biological Resources Bank (BRC) “Interactions Gène-
Environnement en Physiopathologie CardioVasculaire”
(IGE-PCV) in Nancy, East of France. All subjects gave
written informed consent and the project protocol was
approved by the local ethics committee of each centre.
Study population
Both Discovery (phase 1) and Replication (phase 2)
populations were homogenous and selected in the BRCIGE-PCV on the basis of the following criteria: (1) no
antihypertensive drug therapy at recruitment; (2) complete
clinical and genotypic data available; and (3) European
origin.
The phase 1 enrolled 1,912 unrelated adults (51.13 ±
10.02 years, 51.3% women) recruited during free medical
check-ups at the Center of Preventive Medicine of
Vandœuvre-lès-Nancy in the East of France. They were
Caucasians and born in France for three generations. As
our purpose was to assess BP as a continuous trait, in a
case-only design, normotensive and hypertensive subjects
were included (for hypertensive individuals, data were
gathered before the prescription of any medication).
The phase 2 enrolled 1,755 unrelated healthy Europeans
from Crete (Greece); Belfast (Northern Ireland) and Lisbon
(Portugal) (42.06 ± 9.89 years, 33% women) involved in the
ApoEurope Project [19].
Clinical and biological data used for this study were
collected at entrance before any eventual drug prescrip-
tion following consultation for both populations.
Clinical and biological data collection
SBP and DBP were measured under constant temperature
(19°C-21°C) and standardized conditions (supine position)
using a manual sphygmomanometer (Colonne à mercure,
Mercurius) by expert nurses. The recorded values were
the means of 3 readings on 20 min intervals. An adjustable
BP cuff was used to correct errors due to variations in arm
circumference [20]. All individuals underwent complete
medical examination including anthropometric and
biochemical measurements collected with standardized
methods [21].
Genotyping assays
Concerning the selection of assessed SNPs, 1/3 (35 SNPs
in 15 genes) were chosen from the “Cardio-Vascular Dis-
ease 35” assay, a multi-locus genotyping assay developed
in collaboration with Roche Molecular Systems [22].
These SNPs were candidate markers for CVD risk [22]
specifically involved in the development and progression
of atherosclerotic plaque. The 2/3 remaining were chosen
based on the bibliography and on internal investigations
performed predominantly in small to medium sized
samples [7,23] (Additional file 1: Table S1).
Genotyping was performed using a multilocus assay
with an immobilized probe approach designed by Roche
Molecular Systems, Pleasanton, California, USA [22,24]
and described in detail in the Additional file 1.
PolyPhen analysis of nonsynonymous SNPs
The prediction of possible impact of nonsynonymous
(ns) SNPs on the structure and function of their specific
protein was performed using PolyPhen [25].
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Statistical analyses were performed using the SPSSW sta-
tistical software version 16.0 (SPSS, Inc, Chicago, Illi-
nois) and Plink v01.7 [26].
Polymorphisms with minor allele frequencies (MAF)
less than 2% or deviating from Hardy-Weinberg equilib-
rium (HWE) were excluded from individual analyses.
However, for epistatic interaction analyses we included all
SNPs as low MAF may identify an epistatic phenomenon.
The independent effect of the 100 genetic variants on SBP
and DBP were determined assuming additive models using
the minor allele as the reference group. Age, gender and
body mass index (BMI)-adjusted linear regressions were
performed and associations were considered significant
when p-values adjusted for multiple testing (Bonferroni cor-
rection) were ≤ 0.05 and only if a posteriori-calculated statis-
tical powers [calculated with SPSSW 16.0] were ≥ 80%.
We determined if the variants individually associated
in our study were previously reported or in linkage-
disequilibrium (LD) with variants previously reported in
the literature, notably on GWAS. SNPs with a correl-
ation coefficient ≥ 0.8 were considered in LD and then
replicated.
Two-locus additive epistasis was defined as significant
statistical interaction between two SNPs [27] with an a
posteriori-calculated statistical power [calculated with
SPSSW 16.0] ≥ 80%. All possible 2×2 combinations be-
tween the 100 SNPs involved in the discovery study
(phase 1) were tested on a linear additive model (p-value
≤ 0.05) adjusted for age, gender and BMI in the Discov-
ery population. In phase 2, similar models were applied
for the replication of the two significant epistatic
interactions observed in phase 1.
Values of SBP and DBP were log-transformed in order
to normalise their distribution.
Results
Characteristics of the study populations are presented in
Table 1.
Assessed genetic variants
All genes following MAF quality control were consistent with
HWE (data not shown). Among the 100 SNPs investigated,Table 1 Mean characteristics of studied individuals
Characteristics Discovery population Replication population
N (% women) 1,912 (51.3%) 1,755 (33%)
Age (years) 51.13 ± 10.02 42.06 ± 9.89
BMI (kg/m2) 26.01 ± 3.75 26.23 ± 4.11
SBP (mmHg) 142.86 ± 21.47 128.62 ± 17.69
DBP (mmHg) 87.49 ± 14.26 81.15 ± 10.93
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic
blood pressure.50 were nonsynonymous, and according to Polyphen [25],
rs1800888, rs5742912, rs7412, rs5361 and rs2228570 were
related to a modification in their corresponding protein
structures (Additional file 1: Table S1).
Individual association analysis
Associations among genetic variants and BP traits are
shown in Table 2. Nine SNPs in 8 genes including dif-
ferent metabolic pathways were significantly associated
with SBP or DBP: LPL and LDLR (lipid metabolism),
F7 (coagulation factor), AGT1R (BP regulation), CSF2,
IL1B, TGFB1 and VDR (inflammatory pathways). Seven
SNPs were associated with both SBP and DBP levels;
rs5186 in AGT1R (Padjusted≤0.027), rs25882 in CSF2
(Padjusted≤3.83×10
-04), rs5742910 in F7 (Padjusted≤0.03),
rs1143634 in IL1B (Padjusted≤0.049), rs5742911 in LDLR
(Padjusted≤0.035) rs1800469 in TGFB1 (Padjusted≤0.036)
and rs2228570 in VDR (Padjusted≤9.48×10
-04).
Age, gender and BMI were not significantly interacting
with these SNPs.
Our imputation analyses showed that none of these
significant SNPs have been reported or were in LD
(r2 < 0.80) with genetic variants highlighted in previous
GWAS [14,15].
Epistatic interaction with BP
Epistatic interactions with BP are shown in Table 3.
Two epistases: VCAM1 (rs1041163, Upstream, chromo-
some 1) * APOB (rs1367117, exonic, chromosome 2) and
SCGB1A1 (rs3741240, 5’ UTR, chromosome 11) * LPL
(rs1800590, 5’ UTR, chromosome 8) were observed for
both SBP and DBP in the discovery set (P≤0.04 and
P≤0.03 respectively). We intended to replicate these
interactions in phase 2 and observed significant interactions
for DBP only (P=0.045 and P=0.05 respectively). Age, gen-
der and BMI had no significant effect on these interactions.
Although we found no clear interaction pattern be-
tween phases 1 and 2, these interactions were putatively
functional according to PolyPhen.
Discussion
Even at early stages, HT is a major cause of disability
and death for millions of people worldwide [1]. Observa-
tional studies involving more than 1 million adults from
61 prospective studies have indicated that death from
HT-associated diseases (both IHD and stroke) increases
linearly from BP levels as low as 115/75 mmHg among
middle age and elderly individuals [28]. Therefore, isolat-
ing genetic variations that influence BP may have major
implications for public health; however, individual genes
have only shown a modest effect so far [29]. It is there-
fore essential to study possible epistatic gene interactions
in order to identify gene combinations that synergistic-
ally influence BP regulation and HT.











*106165 rs5186 A 3’UTR 28.933 8.34×10-04 0.027 −0.051 0.032 SBP
6.96×10-03 0.041 −0.045 0.051 DBP
CSF2 *138960 rs25882 T Exonic 25.596 4.67×10-06 3.83×10-04 0.124 0.030 SBP
7.25×10-07 5.94×10-05 0.148 0.048 DBP
F7 227500 rs5742910 NA Upstream 15.024 3.72×10-04 0.030 −0.028 0.041 SBP
3.34×10-04 0.027 −0.042 0.065 DBP
rs6046 C Exonic 12.874 5.33×10-04 0.044 −0.028 0.044 SBP
IL1B *147720 rs1143634 C Exonic 19.397 4.21×10-04 0.035 −0.044 0.035 SBP
5.92×10-04 0.049 −0.052 0.056 DBP
LDLR 606945 rs5742911 A 3’UTR 32.308 4.31×10-04 0.035 0.06 0.029 SBP
1.17×10-04 0.010 0.071 0.047 DBP
LPL 609708 rs1800590 G 5’UTR 2.586 3.46×10-04 0.028 0.076 0.088 SBP
TGFB1 *190180 rs1800469 C Upstream 29.048 4.44×10-04 0.036 −0.026 0.030 SBP
9.77×10-06 8.02×10-04 −0.038 0.047 DBP
VDR *601769 rs2228570 T Exonic 40.139 1.16×10-05 9.48×10-04 −0.012 0.028 SBP
6.02×10-06 4.93×10-04 −0.009 0.045 DBP
SNP: single nucleotide polymorphism, MAF: minor allele frequency, beta: regression coefficient corresponding to the minor allele of each SNP, SE: standard error,
SBP: systolic blood pressure, DBP: diastolic blood pressure.
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to diverse biological pathways (lipid metabolism, coagu-
lation, BP regulation and inflammatory pathways) to BP
variations. Genetic variation may be responsible for
hypertensive phenotypes by altering either the structure
of encoded proteins or gene expression [14]. Through
an in silico analysis (PolyPhen), 5 SNPs were found to
have possible functional effects through altering the
corresponding protein structure (rs1800888, rs5742912,
rs7412, rs5361 and rs2228570). In contrast, rs1800469 in
TGFB1 has been reported to be associated with increased
TGFB1 gene transcription and plasma protein levels [30],
suggesting altered gene expression [30,31]. Similarly,
rs5742910 and nsSNP rs6046 in F7 have been previously
reported to be associated with a 1/3 decrease in F7 plasma
levels [7]. These 2 SNPs have also been previously
associated with BP in a population derived from the BRC
IGE-PCV [7]. Combined with previous data, our finding
suggests that these 2 SNPs are associated with BP possibly
due to modifications in gene expression and alterations in
plasma protein levels.
Polymorphisms may also affect gene expression by
disrupting microRNA binding (miRNA). For example, in
the present study, rs5186 C allele of AGTR1 disrupts
binding of miR155 to its complementary AGTR1 mRNA
[32,33] resulting in an overall increase in gene expres-
sion. A molecular mechanism for miR155 interactionwith its polymorphic target rs5186A (3’ UTR of AGTR1)
has also been proposed [33].
Additionally, it is reported that rs1800590 polymorph-
ism of LPL affects lipoprotein lipase enzyme function
[34,35]. Similarly, the coding nsSNP rs2228570 in VDR
introduces an amino acid substitution (Met1Thr) that
may modify the structure of the encoded protein,
according to Polyphen [25]. Thus, the influences of LPL
and VDR polymorphisms on BP may be the result of
modifications in their protein structure and resulting
changes in protein activity.
Epistatic interactions may also play a pivotal role in
the discrepancies found among genetic studies. There
are numerous reports that these interactions may iden-
tify genetic markers that are not captured by individual
marker analysis and/or revealed by the combinatory ef-
fect of loci in other pathways [13,18]. Herein we
observed two epistatic interactions common for all BP
traits: VCAM1 (rs1041163) * APOB (rs1367117) and SCGB1A1
(rs3741240) * LPL (rs1800590) (Table 3). Interestingly, only
rs1800590 common allele was independently associated to an
increase of SBP (Padjusted=0.028, SE=0.088, β=0.076; Table 2).
Its combination with rs3741240 minor allele showed
an inversion of this effect on SBP as common homozy-
gous individuals had lower SBP than heterozygous.
SNP rs3741240 also revealed that rs1800590 was
associated to DBP as well.
Table 3 Epistatic interactions between genetic variants associated with blood pressure
A: Epistatic interactions in Discovery population between VCAM1 (rs1041163) * APOB (rs1367117) on SBP (P=0.04)
SBP rs1041163
11 12 22 N TOT
rs1367117 11 141.47 ± 21.31 (487) 138.55 ± 22.08 (213) 152.55 ± 19.69 (30) 730
12 137.27 ± 21.22 (468) 140.67 ± 21.27 (182) 146.15 ± 20.68 (28) 678
22 139.78 ± 19.24 (111) 135.43 ± 24.96 (41) 139.83 ± 26.73 (8) 160
N TOT 1066 436 66 1568
B: Epistatic interactions in Discovery population between VCAM1 (rs1041163) * APOB (rs1367117) on DBP (P=0.027)
DBP rs1041163
11 12 22 N TOT
rs1367117 11 86.77 ± 14.47 (495) 85.35 ± 13.10 (232) 87.95 ± 14.22 (37) 764
12 87.97 ± 14.05 (436) 92.11 ± 11.99 (149) 88.04 ± 13.41 (21) 606
22 90.06 ± 14.08 (135) 87.92 ± 11.19 (55) 96.00 (8) 198
N TOT 1066 436 66 1568
C: Epistatic interactions in Discovery population between SCGB1A1 (rs3741240) * LPL (rs1800590) on SBP (P=0.02)
SBP rs3741240
11 12 22 N TOT
rs1800590 11 87.66 ± 14.31 (846) 87.14 ± 14.25 (739) 87.95 ± 14.22 (217) 1802
12 86.85 ± 13.89 (46) 94.14 ± 11.41 (34) 88.04 ± 13.41 (11) 91
22 (0) 99.30 ± 2.45 (4) 96.00 (1) 5
N TOT 892 777 229 1898
D: Epistatic interactions in Discovery population between SCGB1A1 (rs3741240) * LPL (rs1801177) on DBP (P=0.03)
DBP rs3741240
11 12 22 N TOT
rs1801177 11 87.66 ± 14.36 (856) 87.32 ± 14.22 (751) 88.05 ± 14.19 (219) 1826
12 86.55 ± 12.38 (36) 92.91 ± 12.23 (26) 85.65 ± 13.72 (9) 71
22 (0) (0) 96.00 (1) 1
N TOT 892 777 229 1898
E: Epistatic interactions in Replication population between VCAM1 (rs1041163) * APOB (rs1367117) on DBP (P=0.045)
DBP rs1041163
11 12 22 N TOT
rs1367117 11 81.73 ± 0.47 (509) 80.80 ± 0.74 (241) 85.00 ± 2.07 (29) 779
12 80.88 ± 0.49 (441) 80.55 ± 0.84 (183) 78.25 ± 2.69 (30) 654
22 80.05 ± 1.11 (92) 83.71 ± 1.81 (46) 83.16 ± 3.19 (6) 144
N TOT 1042 470 65 1577
F: Epistatic interactions in Replication population between SCGB1A1 (rs3741240) * LPL (rs1801177) on DBP (P=0.05)
DBP rs3741240
11 12 22 N TOT
rs1800590 11 80.58 ± 0.41 (681) 81.62 ± 0.41 (684) 81.09 ± 0.90 (168) 1533
12 83.60 ± 2.04 (29) 81.76 ± 1.94 (21) 86.31 ± 3.02 (11) 61
22 60.00 (1) 78.75 ± 1.2 (2) (0) 3
N TOT 711 707 179 1597
DBP: diastolic blood pressure.
SBP: systolic blood pressure.
Mean value ± SE (sample size).
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and LPL (rs1800590) and the subsequent inversion
phenomenon were also observed in an independent
population (phase 2) on DBP.
In silico review showed that rs3741240 is a potentially
functional SNP inhibiting phospholipase A2 [36] and de-
creasing plasma levels of high-density lipoprotein choles-
terol (HDL-C) [37]. Taken together, LPL and SCGB1A1
may interact through HDL-C to influence BP.
The epistatic interactions that we may have identified be-
tween VCAM1 (rs1041163) * APOB (rs1367117) highlighted
original associations with BP as neither rs1041163 nor
rs1367117 was independently associated to any of the traits
studied. This highlighted the fact that important genetic
regulation pathways could be missed when using conven-
tional single SNP-trait approaches. Whereas rs1041163 is a
nonfunctional SNP, rs1367117 may result in an altered
protein structure according to PolyPhen. Human stud-
ies have reported significant correlations between
Apolipoprotein B (APOB), the main component of
low-density lipoprotein cholesterol, and VCAM1 in
the context of HT. Hubel et al. [38] have reported sig-
nificant correlations between soluble levels of APOB
and VCAM1 in women with endothelial dysfunction
and HT as a result of preeclampsia.
Nevertheless, previous candidate gene studies have
revealed other epistatic interactions in BP phenotypes
[18,39] in non-European populations. In a cross-
sectional study conducted in 402 middle aged and eld-
erly Japanese, Misono et al. [18] demonstrated that
individuals carrying a combination of ADRB2 Gly/Gly
and NOS3 Glu/Glu genotypes had higher hypertensive
risk. Moreover, Kohara et al. [39] in a case–control
study conducted in 9,700 subjects reported that epi-
static interactions are associated with increased risk of
HT. Combined with our observations, there is insights
that numerous epistatic interactions involving multiple
physiological pathways influence BP levels and HT
risk.
Strengths and limitations
Genetic interactions have been little investigated by the
scientific community so far. Indeed, gathering large in-
dependent populations allowing to investigate these
phenomenon is complicated as the MAF may differ.
The present study showed significant interactions in
both phases 1 and 2 for only one of the traits: DBP, with
no clear interaction pattern certainly due to the limited
size of our replication population. However, our results
are strengthened by the in silico approach (PolyPhen) and
previous biochemical and molecular studies that have
provided biological evidence for our putative functional
epistatic interactions. Nevertheless, to confirm our epi-
static interactions reproducibility, reported SNPs shouldbe tested in a GWAS with high resolution arrays and
higher genome-wide covering in a large population.
Conclusions and perspectives
In summary, we identified (a) susceptibility genes
associated with BP including LPL and LDLR (lipid me-
tabolism), F7 (coagulation factor), AGT1R (BP regulation),
TNF, IL1B, CSF2, TGFB1, LTA and VDR (inflammation);
(b) epistatic interactions between putative functional SNPs
involved in lipid metabolism: LPL (rs1800590) and APOB
(rs1367117), inflammation: SCGB1A1 (rs3741240) and cel-
lular adhesion: VCAM1 (rs1041163). Our results were not
previously reported in the literature (previous GWAS stu-
dies) and they were not in LD with other SNPs identified
in these studies concerning BP. It is important to
emphasize that these findings may provide insight into
novel pathophysiological mechanisms underlying HT and
they may provide future therapeutic targets.
Additional file
Additional file 1: Genotyping assays. Table S1. Summary of
investigated genetic variants. Table S2. Minor allele frequency of the
investigated SNPs in ApoEurope.
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